Navigation Links
Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus

British Drug company, PowerMed is seeking approval for conducting the first human trials of experimental vaccine against the deadly strain of avian flu virus H5N1//.

The World Health Organisation has reported 97 human cases of avian flu since December 2003, with at least 53 deaths.

The company has submitted its plans for the trial to the UK Medicines and Healthcare Products Regulatory Agency. The Agency is expected to approve the vaccine for the trial to proceed at a London hospital.

While the government has stockpiled antiviral drugs Tamiflu and Relenza against avian flu the vaccine could help to limit the infection's spread if a pandemic strain emerges. Unlike most other conventional vaccines that use weakened strains or fragments of the harmful virus, this test vaccine uses strands of DNA , making it a faster and more cost effective option.

During the trial, the volunteers are expected to be vaccinated with a handheld device that will blast harmless, microscopic gold particles coated in the vaccine into the upper arm at supersonic speeds.

Earlier this year tests of a DNA vaccine that was designed to give protection against seasonal flu showed that it offered 100% protection, based on the immune response of volunteers. The DNA vaccine against avian flu has been tested only in animals, so far, where it has proved successful.

According to John Beadle, chief medical officer of the Oxford-based company PowderMed, ‘Our tests have shown that it stops the infection entirely, to the point that we can't even measure the virus in the animals afterwards.’

The company's research has suggested that humans would require two doses of the vaccine, a prime and a boost. Half a kilogram of DNA would suffice for two doses of the vaccine for everyone in Britain.

The details of the trial are put up on the government's website, Clinicaltrials.gov where the company has statecd that was seeking 75 voluntee rs for the trial at Guy's drug research unit in London.

If the trial goes ahead as planned, volunteers will be tested over several months to monitor how long the vaccine remains effective. Preliminary results are expected in January next year.


'"/>




Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Drug Company Admits Knowledge Of Side Effects In Monkeys
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. Indian Training Company To Train Children In Dubai, Sharjah
10. GE Healthcare to Acquire Swedish Medical Company
11. New Company Will Seek Drugs Against Diabetes and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2017)... ... 2017 , ... An increase in wetter weather in the Northern California area ... that; a humdinger of an allergy season. A relief from drought conditions is most ... grass and weed pollen. , “Our patients have been reporting the typical allergy ...
(Date:6/25/2017)... ... ... is Men’s Health Month and the focus is on prostate cancer. Second only ... and the third most common cause of cancer related death today; lung cancer remains in ... diagnosed with prostate cancer during his lifetime. Those at highest risk are men ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and ... so that visits to the dentist fit into their patients’ busy lifestyles. Dental365 ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, ... proposed healthcare bill to repeal and replace the Affordable Care Act (ACA). Like ... make significant cuts to Medicaid, a public health insurance program for low-income children, ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology: